Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK10 | P53779 | 9/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | ESR1 | P03372 | 3/20 | 0.38 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.38 |
| ▸ | COMT | P21964 | 1/20 | 0.38 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.38 |
| ▸ | CACNG8 | Q8WXS5 | 1/20 | 0.38 |
| ▸ | CACNG2 | Q9Y698 | 1/20 | 0.38 |
| ▸ | MAPK9 | P45984 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21081242 | 0.94 | MAPK10 (0.47) | MAPK10HPGDESR1ESR2COMT | |
| SCHEMBL21081323 | 0.90 | MAPK10 (0.49) | MAPK10ESR1ESR2COMTGRIA1 | |
| SCHEMBL21081264 | 0.87 | RECQL (0.48) | HPGDRAB9AESR1ESR2COMT | |
| SCHEMBL21081263 | 0.87 | ESR2 (0.43) | MAPK10RAB9AESR1ESR2COMT | |
| SCHEMBL21081249 | 0.86 | MAPK10 (0.51) | MAPK10RAB9AESR1ESR2GRIA1 | |
| SCHEMBL21081245 | 0.85 | ESR1 (0.49) | HPGDRAB9AESR1ESR2COMT | |
| SCHEMBL21081276 | 0.83 | MDM2 (0.47) | RAB9AESR1ESR2COMTGRIA1 | |
| SCHEMBL21081230 | 0.83 | ESR1 (0.55) | HPGDRAB9AESR1ESR2COMT | |
| SCHEMBL21081247 | 0.82 | MAPK10 (0.46) | MAPK10RAB9ACOMTALDH1A1 | |
| SCHEMBL21081231 | 0.81 | RECQL (0.51) | HPGDRAB9AESR1ESR2GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190173021-A1 | NITROGEN HETEROCYCLE-FUSED BENZENE-BENZIMIDAZOLE ORGANIC COMPOUND, DISPLAY PANEL AND DISPLAY APPARATUS | WUHAN TIANMA MICRO-ELECTRONICS CO., LTD. (CN) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190173021-A1 | NITROGEN HETEROCYCLE-FUSED BENZENE-BENZIMIDAZOLE ORGANIC COMPOUND, DISPLAY PANEL AND DISPLAY APPARATUS | OCIAD1, OCIAD2, CTNND1 | MAPK10 2838/4885HPGD 437/4885RAB9A 2660/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.